Healthtech Patient21 has raised €100 million in a Series C funding round led by new investor Pitango, joined by Bertelsmann Investments and Artian and supported by existing investors Target Global, Piton Capital, PICO Venture Partners and angel investors, including Mario Kohle and Maria Raga.
Healthtech Patient21 has raised €100 million in a Series C funding round led by new investor Pitango, joined by Bertelsmann Investments and Artian and supported by existing investors Target Global, Piton Capital, PICO Venture Partners and angel investors, including Mario Kohle and Maria Raga.
Growth debt from IPF Partners, which constitutes a small part of the funding, has been secured to complement the equity raise, with the investment set to be used to drive the development the company’s software platform and expand from Germany into additional European markets.
Patient21’s hybrid model combines its self-developed software with a network of owned and operated physical clinics, enabling end-to-end control of the patient journey in contrast to digital-only solutions. The business was founded by serial entrepreneur Christopher Muhr (CEO), who has launched and exited several high profile tech companies, and Nicolas Hantzsch (COO). The pair came up with the idea from their own first-hand experience of the European healthcare system, having both undergone cancer treatment several years earlier.
